NeoChord DS1000 vs. Surgery for Mitral Valve Regurgitation
(ReChord Trial)
Trial Summary
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Research shows that the NeoChord DS1000 System, which uses a minimally invasive technique to repair the mitral valve, has been found to be a safe and effective treatment for mitral valve regurgitation. Studies indicate promising outcomes with minor complications, suggesting it is a feasible alternative to traditional surgery.
12345The NeoChord DS1000 system has been shown to be generally safe in humans, with studies indicating it is a feasible procedure with minor complications and promising outcomes for treating mitral valve regurgitation.
34567The NeoChord DS1000 treatment is unique because it is a minimally invasive procedure that repairs the mitral valve by implanting artificial chords through a small incision in the chest, without stopping the heart or using a heart-lung machine. This approach allows for a quicker recovery and fewer complications compared to traditional open-heart surgery.
13457Eligibility Criteria
This trial is for adults with moderate to severe degenerative mitral valve regurgitation who are suitable for standard surgical repair. Candidates should have specific conditions of the heart's mitral valve, like anterior leaflet prolapse, and must not have had prior mitral surgery or other cardiac procedures within the last 3 months.Inclusion Criteria
Exclusion Criteria
Participant Groups
- Degenerative mitral valve regurgitation
- Mitral valve prolapse
- Investigational Device Exemption (IDE) approval for clinical trial; not commercially approved